Article Text

other Versions

PDF
Original article
A randomised controlled trial of small particle inhaled steroids in refractory eosinophilic asthma (SPIRA)
  1. David Hodgson1,
  2. John Anderson1,
  3. Catherine Reynolds1,
  4. Garry Meakin1,
  5. Helen Bailey1,
  6. Ian Pavord2,
  7. Dominick Shaw1,
  8. Tim Harrison1
  1. 1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  2. 2Nuffield Department of Medicine, University of Oxford, Oxford, UK
  1. Correspondence to Dr Tim Harrison, Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; tim.harrison{at}nottingham.ac.uk

Abstract

Background Some patients with refractory asthma have evidence of uncontrolled eosinophilic inflammation in the distal airways. While traditional formulations of inhaled steroids settle predominantly in the large airways, newer formulations with an extra-fine particle size have a more peripheral pattern of deposition. Specifically treating distal airway inflammation may improve asthma control.

Methods 30 patients with refractory asthma despite high dose inhaled corticosteroids were identified as having persistent airway eosinophilia. Following 2 weeks of prednisolone 30 mg, patients demonstrating an improvement in asthma control were randomised to receive either ciclesonide 320 µg twice daily or placebo in addition to usual maintenance therapy for 8 weeks. The primary outcome measure was sputum eosinophil count at week 8. Alveolar nitric oxide was measured as a marker of distal airway inflammation.

Results There was continued suppression of differential sputum eosinophil counts with ciclesonide (median 2.3%) but not placebo (median 4.5%) though the between-group difference was not significant. When patients who had changed their maintenance prednisolone dose during the trial were excluded the difference between groups was significant (1.4% vs 4.5%, p=0.028). Though alveolar nitric oxide decreased with ciclesonide the value did not reach statistical significance.

Conclusions These data demonstrate that patients with ongoing eosinophilic inflammation are not truly refractory, and that suppression of airway eosinophilia may be maintained with additional inhaled corticosteroid. Further work is needed with a focus on patient-orientated outcome measures such as exacerbation rate, with additional tests of small airway function.

Trial registration number NCT01171365. Protocol available at http://www.clinicaltrials.gov.

  • Asthma
  • Inhaler devices
  • Pulmonary eosinophilia

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.